Kinesis Pharma Singapore: accelerating drug development in South-East Asia
Since 2010 Kinesis Pharma operates a regional office in Singapore. It provides strategic advice, management consultancy and contract research services to Asian start-up biotech and larger international pharmaceutical companies with a focus on early drug development and registration.
With customers in China, India, Japan, Korea, Taiwan, Thailand and Singapore Kinesis Pharma continues to participate in the fast growing biomedical science industry of the South-East Asian region, an industry that will produce important innovations and promising healthcare solutions in the near future.
Due to its longstanding experience in the different disciplines of drug development, Kinesis Pharma provides its clients with tailor-made strategic advice and hands-on support. This results in an accelerated and more efficient (faster and cheaper) drug development program, an increased product value and a shorter route to commercialization.
A typical program starts with the design of a “roadmap” or drug development plan that outlines the minimal required preclinical and clinical studies, the drug formulation requirements, the timelines, risks and costs that are associated with the development of the product up to a certain milestone. In a next step, Kinesis’ multi-disciplinary experts can assist in a timely execution of the program, making use of Kinesis’ validated network of CROs and CMOs, thereby carefully guiding its clients through the different phases of drug development and (international) registration.
Kees Bol (PhD), CEO of Kinesis Pharma Singapore.